Skip to content

Sensenbrenner Clinical Study

An Observational, Clinical Study to Collect the Medical Data in Order to Determine the Craniofacial Characteristics Through Phenotypic Analysis on Children With Sensenbrenner Treated/Followed at the Hôpital Femme Mère Enfant From 2005

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04184531
Acronym
Sensenbrenner
Enrollment
4
Registered
2019-12-03
Start date
2020-01-31
Completion date
2020-07-31
Last updated
2019-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sensenbrenner Syndrome

Keywords

Sensenbrenner Syndrome, phenotypic analysis, craniofacial characteristics

Brief summary

Sensenbrenner syndrome, also known as cranioectodermal dysplasia (CED), is a rare autosomal-recessive disorder belonging to the ciliopathy group of diseases. It is characterized by a facial dysmorphism, abnormal bone development and ectodermal defects including dental anomalies. CED is a heterogeneous condition with significant phenotypic and molecular variability, whose spectrum may include cases of renal impairment, hepatic fibrosis, retinitis pigmentosa and/or brain anomalies. In many cases, patients develop chronic kidney disease (CKD) due to nephronophthisis between 2 and 6 years of age. The aim of this retrospective study is to better understand the characteristics of this syndrome and to find prognostic factors of CKD. We make the hypothesis that an early diagnosis of the syndrome would lead to a better global management of patients (quality of life, delayed onset of end-stage renal disease).

Interventions

OTHERMedical Data Collect

It is a retrospective clinical study and we will collect only the medical data registered in our hospital software

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Years to 13 Years
Healthy volunteers
No

Inclusion criteria

* Boys and girls. * Aged 3 to 18 years old. * Subjects with a Sensenbrenner's syndrome diagnosis and followed from 2005 * Parents/ legal guardian must provide non opposition prior to participation in the study

Exclusion criteria

* Patients whose parents / legal guardian have object to using the data usually collected for care

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of renal impairment of 4 patients with Sensenbrenner identified with WDR19 and WDR35 mutations, through measurement of level of creatinine in the urine.The result of Creatinine in children with Sensenbrenner syndrome will be collected though study completion an average of 1 year.In many cases, patients with this syndrome develop chronic kidney disease (CKD) due to nephronophthisis between 2 and 6 years of age. Nephronophthisis is characterized by decreased urine concentration ability, chronic tubulointerstitial nephritis, cystic kidney disease and progression towards end-stage kidney disease (ESKD). In this study, we would analyze the renal phenotypes through the level of Creatinine in the urine to detect early-stage kidney disease. All the data will be collected from the patient medical records.

Countries

France

Contacts

Primary ContactFederico DI ROCCO, Pr
federico.dirocco@chu-lyon.fr4 72 35 75 72
Backup ContactJustine BACCHETTA, Pr
justine.bacchetta@chu-lyon.fr4 27 85 61 30

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026